Janus Henderson Forty Fund’s Updates on Eli Lilly and Company (LLY)

robot
Abstract generation in progress

Janus Henderson Forty Fund released its Q4 2025 investor letter, highlighting Eli Lilly and Company (LLY) as a significant contributor. The pharmaceutical giant saw strong performance driven by its GLP-1 weight loss products, Mounjaro and Zepbound, and promising pipeline drugs. Despite LLY’s strong 2025 results, the fund suggests AI stocks may offer higher and quicker returns for investors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin